MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer

Phase 1 Completed 6 enrolled University Hospital, Ghent Kom Op Tegen Kanker · collab University Ghent · collab

NaSingle-groupOpen-labelTreatment

Summary

MIDRIXNEO-LUNG is a novel autologous dendritic cell vaccine for non-small cell lung cancer patients, targeting neoantigens predicted from the patient-individual tumor's mutanome. This first-in-human study aims to primarily establish maximal tolerated dose of MIDRIXNEO-LUNG administered i.v.

Timeline

Start: 2019-08-26
Primary completion: 2024-02-01
Completion: 2025-03-03

Publications

Background Brabants E, Heyns K, De Smet S, Devreker P, Ingels J, De Cabooter N, Debacker V, Dullaers M, VAN Meerbeeck JP, Vandekerckhove B, Vermaelen KY. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination. Cytotherapy. 2018 Sep;20(9):1164-1181. doi: 10.1016/j.jcyt.2018.06.006. Epub 2018 Aug 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MIDRIXNEO-LUNG	Cell therapy	1e+07 cells	Intravenous
Subject	MIDRIXNEO-LUNG	Cell therapy	2e+07 cells	Intravenous
Subject	MIDRIXNEO-LUNG	Cell therapy	4e+07 cells	Intravenous
Subject	MIDRIXNEO-LUNG	Cell therapy	8e+07 cells	Intravenous
Subject	MIDRIXNEO-LUNG	Cell therapy	1e+08 cells	Intravenous

MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications